Twist Bioscience Co. (NASDAQ:TWST) Shares Acquired by GAMMA Investing LLC

GAMMA Investing LLC increased its holdings in shares of Twist Bioscience Co. (NASDAQ:TWST) by 6,499.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 29,366 shares of the company’s stock after buying an additional 28,921 shares during the period. GAMMA Investing LLC’s holdings in Twist Bioscience were worth $1,153,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently made changes to their positions in TWST. First Light Asset Management LLC purchased a new position in shares of Twist Bioscience during the 4th quarter valued at approximately $56,984,000. Marshall Wace LLP lifted its position in shares of Twist Bioscience by 15,927.8% during the 4th quarter. Marshall Wace LLP now owns 846,107 shares of the company’s stock valued at $39,319,000 after buying an additional 840,828 shares in the last quarter. Thrivent Financial for Lutherans lifted its position in shares of Twist Bioscience by 54.6% during the 4th quarter. Thrivent Financial for Lutherans now owns 1,505,753 shares of the company’s stock valued at $69,972,000 after buying an additional 532,040 shares in the last quarter. American Century Companies Inc. lifted its position in shares of Twist Bioscience by 63.5% during the 4th quarter. American Century Companies Inc. now owns 756,352 shares of the company’s stock valued at $35,148,000 after buying an additional 293,751 shares in the last quarter. Finally, ARK Investment Management LLC lifted its position in shares of Twist Bioscience by 4.4% during the 4th quarter. ARK Investment Management LLC now owns 5,595,865 shares of the company’s stock valued at $260,040,000 after buying an additional 237,772 shares in the last quarter.

Twist Bioscience Stock Down 0.3%

Shares of TWST opened at $33.52 on Monday. Twist Bioscience Co. has a 52-week low of $27.12 and a 52-week high of $60.90. The company has a market capitalization of $2.01 billion, a PE ratio of -9.92 and a beta of 2.38. The stock has a fifty day simple moving average of $34.05 and a two-hundred day simple moving average of $41.52. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST) last issued its earnings results on Monday, May 5th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.10). Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The company had revenue of $92.79 million during the quarter, compared to analyst estimates of $92.00 million. As a group, equities analysts forecast that Twist Bioscience Co. will post -2.12 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the company. JPMorgan Chase & Co. decreased their target price on Twist Bioscience from $40.00 to $33.00 and set an “underweight” rating on the stock in a research report on Tuesday, May 6th. Guggenheim restated a “buy” rating and issued a $50.00 price objective on shares of Twist Bioscience in a report on Tuesday, May 6th. Barclays decreased their price objective on Twist Bioscience from $58.00 to $45.00 and set an “overweight” rating on the stock in a report on Thursday, April 10th. The Goldman Sachs Group decreased their price objective on Twist Bioscience from $55.00 to $48.00 and set a “buy” rating on the stock in a report on Tuesday, May 6th. Finally, Robert W. Baird decreased their price objective on Twist Bioscience from $54.00 to $44.00 and set an “outperform” rating on the stock in a report on Tuesday, May 6th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $50.40.

Insiders Place Their Bets

In related news, SVP Paula Green sold 1,101 shares of the firm’s stock in a transaction dated Monday, May 5th. The stock was sold at an average price of $37.65, for a total transaction of $41,452.65. Following the completion of the sale, the senior vice president now directly owns 129,380 shares of the company’s stock, valued at approximately $4,871,157. This trade represents a 0.84% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Emily M. Leproust sold 1,726 shares of the firm’s stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $41.68, for a total value of $71,939.68. Following the sale, the chief executive officer now directly owns 660,966 shares of the company’s stock, valued at $27,549,062.88. The trade was a 0.26% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 22,920 shares of company stock valued at $814,067 in the last three months. 3.01% of the stock is currently owned by insiders.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.